Clovis Oncology Inc (NASDAQ:CLVS)
| 0.6899 Delayed Data As of May 27 |  +0.0157 / +2.33%Today’s Change | 0.61 Today|||52-Week Range 7.24 | -74.54% Year-to-Date |
Latest CLVS News | Press Releases
| 2 Biotech Stocks That Could Go Parabolic May 16 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 0.67 |
| Today’s open | 0.70 |
| Day’s range | 0.62 - 0.70 |
| Volume | 214,457 |
| Average volume (3 months) | 9,833,179 |
| Market cap | $104.7M |
Data as of 4:50pm ET, 05/27/2022
Growth & Valuation
| Earnings growth (last year) | +47.72% |
| Earnings growth (this year) | +27.37% |
| Earnings growth (next 5 years) | +40.19% |
| Revenue growth (last year) | -9.58% |
| P/E ratio | NM |
| Price/Sales | 2.10 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| DAREDare Bioscience Inc | 0.00 | 0.00% |
| TBGNFOxurion NV | 0.00 | 0.00% |
| FBIOFortress Biotech Inc | +0.05 | +6.47% |
| PRTKParatek Pharmaceutic... | +0.07 | +3.91% |
Data as of 4:00pm ET, 05/27/2022
Financials
| Next reporting date | August 3, 2022 |
| EPS forecast (this quarter) | -$0.41 |
| Annual revenue (last year) | $148.8M |
| Annual profit (last year) | -$264.5M |
| Net profit margin | -177.82% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Boulder, Colorado |
Forecasts
